DALLAS, May 31, 2017 -- DocSynk, a healthcare machine learning and artificial intelligence (AI) platform, today announced that its new AI-powered cloud-based app for the healthcare industry has received the “Popular Choice” award in the GE Health Cloud Innovation Challenge, a competition among Independent Software Vendors (ISVs) to develop a cloud-based application that has the greatest potential to improve clinical, financial and/or operational outcomes in healthcare. The company also received an “Honorable Mention” in the Operational Category.
The DocSynk patient app is an intelligent assistant that puts patients at the center and empowers them at every touchpoint within the healthcare system. For providers, the app improves revenue cycle for providers through optimized patient scheduling with in-network providers, cleaner claims and improved cash flow.
“With the GE Health Cloud, GE Healthcare is creating a digital ecosystem of partners and applications that have the potential to solve for healthcare’s greatest clinical, financial and operational challenges,” said Jay Burrell, Senior Vice President of Digital Technology at GE Healthcare.
“We’re pleased to be honored by GE Healthcare,” said Vaidyanatha Siva, CEO and founder of DocSynk. “This app puts the control back in the patients’ hands and improves the revenue cycle turnaround time and positively impacts financial and operational metrics for the providers, so both parties are happy.”
About DocSynk
Founded in 2015, DocSynk is a Dallas-based company with a revolutionary healthcare machine learning and artificial intelligence platform focused on improving critical touchpoints throughout the care continuum. The “DocSynk Disruption” begins with patented machine learning predictive analytics that identify chronic conditions earlier and with greater accuracy than current clinical informatics used by most of healthcare. In addition to predicting at-risk patients, the DocSynk deep learning engine identifies upstream condition precursors and downstream treatment pathways that are quintessential in evidence based medicine. Once the condition is identified, this same technology is applied to help guide the patient through their treatment plan leveraging an AI Chatbot. The seamless coordination from disease identification through treatment administration provides an unparalleled medical consumer experience.
Backed by Naya Ventures, the company is laser-focused on using its patented and ever-improving platform to give patients a second chance at a healthy life.
Contact: Belinda Young, 206-932-3145 [email protected] or Jeremy Young [email protected]


Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 



